Comparative analysis of in vitro processivity of HIV-1 reverse transcriptases containing mutations 65R, 74V, 184V and 65R + 74V

Antiviral Research

Volumn 83, Issue 3, 2009, Pages 317-323

  Sharma, Prem L ^a,b   Nettles, James H ^a,b   Feldman, Anya ^a,b   Rapp, Kimberly ^a,b   Schinazi, Raymond F ^a,b  

^a EMORY CENTER FOR AIDS RESEARCH   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Attenuation; HIV 1; Processivity; Resistance mutation; Reverse transcriptase; Reversion

Indexed keywords

COMPLEMENTARY DNA; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; GENETIC ENGINEERING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; WILD TYPE;

AMINO ACID SUBSTITUTION; DNA; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MUTATION, MISSENSE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 68249096258     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.06.002     Document Type: Article

References (46)

1. Adachi A., Gendelman H.E., Koenig S., Folks T., Willey R., Rabson A., and Martin M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59 (1986) 284-291
2. Arion D., Borkow G., Gu Z., Wainberg M.A., and Parnaik M.A. The K65R mutation confers increased DNA polymerase processivity to HIV-1 reverse transcriptase. J. Biol. Chem. 271 (1996) 19860-19864
3. Back N.K.T., Nijhuis M., Keulen W., Boucher C.A.B., Oude Essink B.B., van Kuilenburg A.B.P., van Gennip A.H., and Berkhout B. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15 (1996) 4040-4049
4. Back N.K., and Berkhout B. Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type1 reverse transcriptase. Antimicrob. Agents Chemother. 41 (1997) 2484-2491
5. Bakhanashvili M. p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase. Oncogene 20 (2001) 7635-7644
6. Bazmi H.Z., Hammond J.L., Cavalcanti S.C., Chu C.K., Schinazi R.F., and Mellors J.W. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-d-dioxolane-guanosine and suppress resistance to 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 44 (2000) 1783-1788
7. Boyer P.L., and Hughes S.H. Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 39 (1995) 1624-1628
8. Boyer P.L., Gao H.Q., and Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at position 74 and 75 via the template primer. Antimicrob. Agents Chemother. 42 (1998) 447-452
9. Deval J., White K.L., Miller M.D., Parkin N.T., Courcambeck J., Halfon P., Selmi B., Boretto J., and Canard B. Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations. J. Biol. Chem. 279 (2004) 509-516
10. Deval J., Navarro J.M., Selmi B., Courcambeck J., Boretto J., Halfon P., Garrido-Urbani S., Sire J., and Canard B. A loss of viral replicative capacity correlates with altered DNA polymerization kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J. Biol. Chem. 279 (2004) 25489-25496
11. Hari M., Loganzo F., Annable T., Tan X., Musto S., Morilla D.B., Nettles J.H., Snyder J.P., and Greenberger L.M. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol. Cancer Ther. 5 (2006) 270-278
12. Harris D., Yadav P.N., and Pandey V.N. Loss of polymerase activity due to Tyr to Phe substitution in the YMDD motif of human immunodeficiency virus type-1 reverse transcriptase is compensated by Met to Val substitution within the same motif. Biochemistry 37 (1998) 9630-9640
13. Henry M., Tourres C., Colson P., Ravaux I., Poizot-Martin I., and Tamalet C. Coexistence of the K65R/L74V and/or K65R/T215Y mutations on the same HIV-1 genome. J. Clin. Virol. 37 (2006) 227-230
14. Hernandez-Santiago B.I., Mathew J.M., Rapp K.L., and Schinazi R.F. Antiviral and cellular metabolism interactions between dexelvucitabine and lamivudine. Antimicrob. Agents Chemother. 51 (2007) 2130-2135
15. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase:implications for drug resistance. Science 282 (1998) 1669-1675
16. Larder B.A., Kemp S.D., and Harrigan P.R. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269 (1995) 696-699
17. Li X., Quan Y., Arts E.J., Li Z., Preston B.D., de Rocquigny H., Roques B.P., Darlix J.L., Kleiman L., Parnaik M.A., and Wainberg M.A. Human immunodeficiency virus type 1 nucleocapsid protein (NCp7) directs specific initiation of minus-strand DNA synthesis primed by human tRNA(Lys3) in vitro: studies of viral RNA molecules mutated in regioons that flank the primer binding site. J. Virol. 70 (1996) 4096-5004
18. McColl D.J., Chappey C., Parkin N.T., and Miller M.D. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database. Antiviral. Ther. 13 (2008) 189-197
19. Miller V., Stark T., Loeliger A.E., and Lange J.M. The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response. HIV Med. 3 (2002) 135-145
20. Nurpeisov V., Hurwitz S.J., and Sharma P.L. Fluorescent dye terminator sequencing methods for quantative determination of replication fitness of HIV-1 containing the codon 74 and 184 mutations in reverse transcriptase. J. Clin. Microbiol. 41 (2003) 3306-3311
21. Olivares I., Sanchez-Merino V., Martinez M.A., Domingo E., Lopez-Galindez C., and Menendez-Arias L. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J. Virol. 73 (1999) 6293-6298
22. Petrella M., and Wainberg M.A. Might the M184V substitution in HIV-1 RT confer clinical benefit?. AIDS Rev. 4 (2002) 224-232
23. Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., and Ferrin T.E. UCSF Chimera-a visualization system for exploratory research and analysis. J. Computational Chem. 25 (2004) 1605-1612
24. Richman D.D. Antiretroviral drug resistance:mechanisms, pathogenesis, clinical significance. Adv. Exp. Med. Biol. 394 (1996) 383-395
25. Røge B.T., Katzenstein T.L., Obel N., Nielsen H., Kirk O., Pedersen C., Mathiesen L., Lundgren J., and Gerstoft J. K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir. Ther. 8 (2003) 173-182
26. Sarafianos S.G., Das K., Clark A.D., Ding Jr. J., Boyer P.L., Hughes S.H., and Arnold E. Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 10027-10032
27. Sarafianos S.G., Clark Jr. A.D., Das K., Tuske S., Birktoft J.J., Ilankumaran P., Ramesha A.R., Sayer J.M., Jerina D.M., Boyer P.L., Hughes S.H., and Arnold E. Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA. EMBO J. 21 (2002) 6614-6624
28. Schinazi R.F., Larder B.A., and Mellors J.W. Mutations in retroviral genes associated with drug resistance (2000-2001 update). Int. Antivir. News 8 (2000) 65-91
29. Schinazi R.F., Lloyd R.M., Nguyen M.-H., Cannon D., Ilksoy N., McMillan A., Chu C.K., Liotta D.C., Bazmi H.Z., and Mellors J.W. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37 (1993) 875-881
30. Shah F.S., Curr K.A., Hamburgh M.E., Parniak M., Mitsuya H., Arnez J.G., and Prasad V.R. Differential influence of nucleoside analog-resistance mutations K65R and L74V on the overall mutation rate and error specificity of human immunodeficiency virus type 1 reverse transcriptase. J. Biol. Chem. 275 (2000) 27037-27044
31. Sharma P.L., Chatis P.A., Dogon A.L., Mayers D.L., McCutchan F.E., Page C., and Crumpacker C.S. AZT-related mutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro RT inhibition assay. Virology 223 (1996) 365-369
32. Sharma P.L., and Crumpacker C.S. Attenuated replication of HIV-1 with a didanosine-selected reverse transcriptase mutation. J. Virol. 71 (1997) 846-8851
33. Sharma P.L., and Crumpacker C.S. Decreased processivity of RT containing a didanosine-selected RT mutation: comparative evaluation of the effect of RT mutations in Leu74Val and Met184Val on viral fitness and RT processivity. J. Virol. 73 (1999) 8448-8456
34. Sharma P.L., Nurpeisov V., Lee K., Skaggs S., Amat C., and Schinazi R.F. Replication-Dependent 65R→K Reversion in human immunodeficiency virus type 1 reverse transcriptase double mutant K65R + L74V. Virology 321 (2004) 222-234
35. St. Clair M.H., Martin J.L., Tudor-Williams G., Bach M.C., Vavro C.L., King D.M., Kellam P., Kemp S.D., and Larder B.A. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253 (1991) 1557-1559
36. Svarovskaia E.S., Feng J.Y., Margot N.A., Myrick F., Goodman D., Ly J.K., White K.L., Kutty N., Wang R., Borroto-Esoda K., and Miller M.D. The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J. Acquir. Immune Defic. Syndr. 48 (2008) 428-436
37. Takahashi H., Matsuda M., Kojima A., Sata T., Andoh T., Kurata T., Nagashima K., and Hall W.W. Human immunodeficiency virus type 1 reverse transcriptase: enhancement of activity by interaction with cellular topoisomerase I. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 5694-5698
38. Tisdale M., Kemp S.D., Parry N.R., and Larder B.A. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 5653-5656
39. Wainberg M.A. The impact of the M184V substitution on drug resistance and viral fitness. Expert Rev. Anti Infect. Ther. 2 (2004) 147-151
40. Wainberg M.A., Drosopoulos W.C., Salomon H., Hsu M., Borkow G., Parniak M.A., Gu Z., Song Q., Manne J., Islam S., Castriota G., and Prasad V.R. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science 271 (1996) 1282-1285
41. Waters L., Nelson M., Manalia S., Bower M., Powels T., Gazzard B., and Stebbing J. The risks and incidence of K65R and L74V mutations and subsequent virologic responses. Clin. Infect. Dis. 46 (2008) 96-100
42. White K.L., Margot N.A., Wrin T., Petropoulos C.J., Miller M.D., and Naeger L.K. Molecular mechanism of resistance to human immunodeficiency virus type 1 on enzyme function and viral replication capacity. Antimicrob. Agents Chemother. 46 (2002) 3437-3446
43. Winters M.A., Shafer R.W., Jellinger R.A., Mamtora G., Gingeras T., and Merigan T.C. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy. Antimicrob. Agents Chemother. 41 (1997) 757-762
44. Wirden M., Malet I., Derache A., Marcelin A.G., Roquebert B., Simon A., Kirstetter M., Joubert L.M., Katlama C., and Calvez V. Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution. AIDS 19 (2005) 630-632
45. Xu, H.T., Martinez-Cajas, J.L., Ntemgwa, M.L., Coutsinos, D., Frankel, F.A., Brenner, B.G., Wainberg, M.A., 2009. Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology 6, 14.
46. Zaccarelli M., Perno C.F., Forbici F., Cingolani A., Liuzzi G., Bertoli A., Trotta M.P., Bellocchi M.C., Di Giambenedetto S., Tozzi V., Gori C., D'Arrigo R., De Longis P., Noto P., Girardi E., De Luca A., and Antinori A. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antivir. Ther. 8 (2003) 51-56